This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ehrenfeld, M Articles by Hidvegi, M Search for Related Content PubMed PubMed Citation Articles by Ehrenfeld, M Articles by Hidvegi, M Social Bookmarking                         What's this?

AVEMAR (a new benzoquinone-containing natural product) administration interferes with the Th2 response in experimental SLE and promotes amelioration of the disease

M Blank

Center for Autoimmune Diseases, The Chaim Sheba Medical Center, Tel-Aviv University, Israel

Y Shoenfeld

Center for Autoimmune Diseases, The Chaim Sheba Medical Center, Tel-Aviv University, Israel; Department of Medicine B, Sheba Medical Center, Tel-Hashomer 52621, IsraelShoenfel{at}post.tau.ac.il

M Hidvegi

The Department of Biochemistry and Food Technology, Budapest University of Technology and Economics, Budapest, Hungary

The potential of oral treatment with AVEMAR (AVEMAR), a new benzoquinone-containing fermentation product of wheat germ, on features of experimental systemic lupus erythematosus (SLE) in naive mice, induced by idiotypic manipulation, was studied. We assessed the effect of AVEMAR on the profile of autoantibody production and the response of Th1=Th2 related cytokines as well as the clinical picture of experimental SLE in the SLE-induced mice.

When the product was given in the pre-immunization period, down-regulation of autoantibody production (anti-dsDNA, mouse 16=6 Id, and anti-histones) following treatment with AVEMAR was noted (eg anti-dsDNA decreased from 0.898 0.097 OD at 405 nm to 0.519 0.103 OD following treatment). This effect was sustained for at least 4 weeks after discontinuation of the therapy. Serological manifestations associated with a delay in Th2 response (IL-4 and IL-10) were recorded (eg IL-4 decreased from 91.7 8.11 to 59.55 7.78 ng =ml in splenocyte condition media). The mice showed normal ESR, WBC and less than 100 mg/dl of protein in the urine in comparison to > 300 mg/dl protein in the SLE non-treated mice.

In conclusion, oral intake of AVEMAR can ameliorate the clinical manifestations of experimental SLE, via affecting the Th1=Th2 network inhibiting Th2 response.

Key Words: AVEMAR • benzoquinone • wheat germ • experimental model • autoantibodies • cytokines

Lupus, Vol. 10, No. 9, 622-627 (2001)
DOI: 10.1191/096120301682430203


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C A Hudson, T K Mondal, L Cao, J Kasten-Jolly, V C Huber, and D A Lawrence The dietary supplement ephedrine induces b-adrenergic mediated exacerbation of systemic lupus erythematosus in NZM391 mice Lupus, April 1, 2005; 14(4): 293 - 307. [Abstract] [PDF]